Revenio Group OyjCHIX:REG1VH 80 EBITDA Margin % is 12.45% as of Mar. 2026, which is 62% below its 10-year median of 33.08. GuruFocus rates CHIX:REG1VH with a GF Score™ of 80/100 and a GF Value™ of €36.95 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Revenio Group Oyj ranks better than 81% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Revenio Group Oyj's EBITDA for the
three
months ended in Mar. 2026 was €3.4 Mil. Revenio Group Oyj's Revenue for the
three
months ended in Mar. 2026 was €27.3 Mil. Therefore, Revenio Group Oyj's EBITDA margin for the quarter that ended in Mar. 2026 was 12.45%.
Revenio Group Oyj (CHIX:REG1Vh) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Revenio Group Oyj EBITDA Margin % Related Terms
Revenio Group Oyj EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:REG1VH vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Revenio Group Oyj's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revenio Group Oyj (CHIX:REG1VH) has a EBITDA Margin % of 12.45% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Revenio Group Oyj and its competitors. This is 62% below median its historical median of 33.08. Over the past decade, Revenio Group Oyj's EBITDA Margin % has ranged from 23.08 to 38.89. According to the industry distribution chart, Revenio Group Oyj ranks #155 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 19%.
Is Revenio Group Oyj's EBITDA Margin % too high?
Revenio Group Oyj's current EBITDA Margin % of 12.45% is 62% below median its 10-year median of 33.08. Over the past 10 years, this metric has ranged from a low of 23.08 to a high of 38.89. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Revenio Group Oyj's value of 12.45% is 66.6% above this industry median. Based on the distribution chart, Revenio Group Oyj ranks #155 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Revenio Group Oyj has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #155 out of 816 companies for EBITDA Margin %. This places Revenio Group Oyj in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Revenio Group Oyj's value of 12.45% is 66.6% above this benchmark. Historically, Revenio Group Oyj's own EBITDA Margin % has ranged from 23.08 to 38.89 over the past decade. While the company's 10-year median is 33.08 vs. the industry median of 7.48, Revenio Group Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current EBITDA Margin % of 12.45% is 66.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Revenio Group Oyj and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current EBITDA Margin % is 12.45%, which is 62% below median its own 10-year median of 33.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Based on GuruFocus' analysis, Revenio Group Oyj (CHIX:REG1VH) is currently considered Significantly Undervalued. The stock's GF Value™ is €36.95, compared to a current price of €16.47 — trading 55.4% below its estimated fair value. The current EBITDA Margin % is 12.45%, which is 62% below median its 10-year median of 33.08 and 66.6% above the Medical Devices & Instruments industry median of 7.48. Revenio Group Oyj's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Revenio Group Oyj (CHIX:REG1VH), the current EBITDA Margin % is 12.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (CHIX:REG1VH) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of €16.47 is trading 55.4% below its estimated GF Value™ of €36.95.
GuruFocus considers Revenio Group Oyj to be Significantly Undervalued.
Key valuation signals for CHIX:REG1VH:
EBITDA Margin %: 12.45% (62% below median its 10-year median of 33.08)
GF Value™: €36.95 vs. price of €16.47 (55.4% below fair value)
Industry Position: 66.6% above the Medical Devices & Instruments median (#155 of 816)
No single metric tells the full story. See the CHIX:REG1VH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
80GF Score
Get the complete analysis for CHIX:REG1VH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:REG1VH has been successfully added to your 
